Beta-thalassemia laboratory findings

Jump to navigation Jump to search

Beta-thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Beta-thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Beta-thalassemia laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Beta-thalassemia laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Beta-thalassemia laboratory findings

CDC on Beta-thalassemia laboratory findings

Beta-thalassemia laboratory findings in the news

Blogs on Beta-thalassemia laboratory findings

Directions to Hospitals Treating Beta-thalassemia

Risk calculators and risk factors for Beta-thalassemia laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

Laboratory findings

  • Various laboratory procedures, including:
    • The automatic hematology analyzer evaluation of red blood cell indices
    • Hemoglobin analysis
    • Quantification of hemoglobin A2 and hemoglobin F

are needed to diagnose thalassemia and abnormal hemoglobin levels.

  • Thalassemic disorders and their carriers can be distinguished using high-performance liquid chromatography (HPLC) and capillary zone electrophoresis (CE) systems. It has been frequently employed to take the role of the manual method. These devices provide accurate, repeatable qualitative and quantitative evaluations of hemoglobin component data. They have made it possible for us to diagnose thalassemia both prenatally and postnatally quickly.
  • DNA analysis may be used to identify specific thalassemia mutations, and several methods have been developed.
  • Real-time polymerase chain reaction (PCR) can also be used to genotype thalassemia, followed by melting curve analysis.
  • DNA sequencing will be used when a mutation cannot be identified using a previous molecular analysis approach.
  • In the most recent years, thalassemia diagnosis has also benefited from genome sequencing by NGS.
•	CBC: CBC reveals severe microcytic hypochromic anemia, with decreased hemoglobin, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH). 

• hemoglobin electrophoresis: In the results of hemoglobin electrophoresis of a normal person, hemoglobin A (HbA) should be about 95-98% of the total hemoglobin and the rest would be hemoglobin A2 and F. Hemoglobin F gets increased in beta-thalassemia

References


Template:WikiDoc Sources